TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 4992682

Group type: EXPERIMENTAL
Intervention: Prenylamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 12
Study: 30883000

Group type: EXPERIMENTAL
Intervention: Tremelimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28034509

Group type: EXPERIMENTAL
Intervention: MAXCOG intervention (four weekly sessions of individualized cognitive rehabilitation)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 55
Study: 28060927

Group type: EXPERIMENTAL
Intervention: FIFA 11+
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Harmoknee
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dynamic warm-up (DWU)
Number of subjects: 16
Study: 24072665

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 200U
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 300U
Number of subjects: 691

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 691
Study: 21875517

Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Thoracic spine manipulation
Number of subjects: 18
Study: 19623190

Group type: EXPERIMENTAL
Intervention: Social marketing-based communications intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 42
Study: 17303070

Group type: EXPERIMENTAL
Intervention: Claustrophobia Scale (CS)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment
Number of subjects: 287
Study: 15519775

Group type: EXPERIMENTAL
Intervention: 70 Gy
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: 80 Gy
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 306
Study: 11766459

Group type: EXPERIMENTAL
Intervention: Increased insulin response (4th quartile)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (2nd and 3rd quartile)
Number of subjects: 184
Study: 9710042

Group type: EXPERIMENTAL
Intervention: Myoblast implantation therapy (60 million myoblasts in one tibialis anterior muscle)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Cyclosporine immunosuppression (5 to 10 mg/kg for 1 year)
Number of subjects: 3
Study: 7838921

Group type: COMPARATOR
Intervention: 0 mg/kg caffeine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg caffeine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3 mg/kg caffeine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6 mg/kg caffeine
Number of subjects: 20
Study: 3414514

Group type: EXPERIMENTAL
Intervention: Nadolol (160 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diltiazem (240 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of nadolol and diltiazem
Number of subjects: 18
Study: 30125790

Group type: EXPERIMENTAL
Intervention: MoodKit (CBT toolkit app)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: MoodPrism (mood tracking app)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: MoodMission (CBT strategy app)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 226
Study: 26208687

Group type: EXPERIMENTAL
Intervention: Maternal zinc supplementation (20 mg/day elemental zinc)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 24509405

Group type: EXPERIMENTAL
Intervention: Custom gutter splint worn nightly for 3 months on the intervention joint
Number of subjects: 26
Study: 23519656

Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR) 4 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Methylphenidate extended release (MPH) 36 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: GXR and MPH combined
Number of subjects: 38

Group type: COMPARATOR
Intervention: GXR, MPH, and GXR and MPH combined
Number of subjects: 38
Study: 21206549

Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (SXB) 9 g nightly
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (SXB) 6 g and 9 g nightly
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (SXB) (all doses)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (SXB)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 18386647

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 16360267

Group type: EXPERIMENTAL
Intervention: Chronic back pain patients
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 11
Study: 14556820

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) for 20 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Observation for 20 weeks
Number of subjects: 16
Study: 10617701

Group type: EXPERIMENTAL
Intervention: DHA supplemented formula
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DHA + arachidonic acid supplemented formula
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (no LCPUFA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Breastfed infants
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Formula-fed infants (all groups)
Number of subjects: 21
Study: 8937798

Group type: EXPERIMENTAL
Intervention: Venous plasma glucose measurements
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 'Arterialized' venous ('heated-hand' technique) plasma glucose measurements
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Capillary plasma glucose measurements
Number of subjects: 9
Study: 7956390

Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (40 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inhaled metaproterenol (15 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of furosemide (40 mg) and metaproterenol (15 mg)
Number of subjects: 24
Study: 3674548

Group type: EXPERIMENTAL
Intervention: Low‐ or high‐dose epimestrol administration schedule
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Salivary progesterone levels in women with infertility
Number of subjects: 52

Group type: COMPARATOR
Intervention: Salivary progesterone levels in eugonadal women
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Saliva/plasma progesterone ratio
Number of subjects: 52
Study: 26836963

Group type: EXPERIMENTAL
Intervention: Single-Incision Laparoscopic Percutaneous Extraperitoneal Closure (SILPEC)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Conventional Laparoscopic Percutaneous Closure (LPEC)
Number of subjects: 109
Study: 24105358

Group type: EXPERIMENTAL
Intervention: Healing Touch (HT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham therapy (Control)
Number of subjects: 41
Study: 23632052

Group type: EXPERIMENTAL
Intervention: Paravertebral block with clonidine
Number of subjects: 60
Study: 20888186

Group type: EXPERIMENTAL
Intervention: ET OLT
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ET OLT+MI
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo control OLT
Number of subjects: 46
Study: 18928378

Group type: EXPERIMENTAL
Intervention: Valacyclovir, 500 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16642611

Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus Chinese medicine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Acupuncture plus Chinese medicine
Number of subjects: 86
Study: 12809175

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 2.5 pg/kg/die of rhGH (GH2.5)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 3.3 pg/kg/die of rhGH (GH3.3)
Number of subjects: 6
Study: 10801246

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (150 microg desogestrel and 30 microg ethinyl estradiol)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (no oral contraceptive)
Number of subjects: 40
Study: 8715782

Group type: EXPERIMENTAL
Intervention: Systematic clinical supervision
Number of subjects: 33

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 33
Study: 1433426

Group type: EXPERIMENTAL
Intervention: 975 mg aspirin 30 min after 10 g activated charcoal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 975 mg aspirin 60 min after 10 g activated charcoal
Number of subjects: 15

Group type: COMPARATOR
Intervention: 975 mg aspirin alone
Number of subjects: 15
Study: 3812052

Group type: EXPERIMENTAL
Intervention: High-nicotine cigarettes (0.9 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low-nicotine cigarettes (0.002 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (candy)
Number of subjects: 42
Study: 31223067

Group type: EXPERIMENTAL
Intervention: Mortality Salience (MS) condition
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Traffic accidents MS condition
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 170
Study: 29384337

Group type: EXPERIMENTAL
Intervention: Nutrition education delivered through e-learning with online reports and behavioural feedback for the experimental group.
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group without online reports and behavioural feedback.
Number of subjects: 95
Study: 26540397

Group type: EXPERIMENTAL
Intervention: IV haloperidol 1 mg every 6 hours
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 24755126

Group type: EXPERIMENTAL
Intervention: Warfarin (1.25 mg/day, with possible increase to 1.75-2.25 mg/day based on INR)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Aspirin (100 mg/day)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 101

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 101
Study: 22995458

Group type: EXPERIMENTAL
Intervention: Rotated head position (>45° head turn)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Neutral head position
Number of subjects: 80
Study: 20435294

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (n = 59)
Number of subjects: 109
Study: 17916662

Group type: EXPERIMENTAL
Intervention: BH(4) (400 mg twice daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 16358138

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (twice a day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no inspiratory muscle training)
Number of subjects: 25
Study: 12756078

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen (20 mg once daily)
Number of subjects: 0
Study: 10625125

Group type: EXPERIMENTAL
Intervention: Telephone contact
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Academic detailing
Number of subjects: 143

Group type: COMPARATOR
Intervention: Direct mail
Number of subjects: 143
Study: 8619011

Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patches (17.5 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 16
Study: 1664253

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (Fragmin) 2,500 XaI U 2 h before operation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (Fragmin) 5,000 XaI U 10 h before surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unfragmented heparin (UH) 5,000 IU before operation
Number of subjects: 24
Study: 7032413

Group type: EXPERIMENTAL
Intervention: Tinidazole (500 mg infusion over 30 minutes before surgery)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Physiological saline (control group)
Number of subjects: 223
Study: 31489852

Group type: EXPERIMENTAL
Intervention: A‐PRF+
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (saline only)
Number of subjects: 40
Study: 29131124

Group type: EXPERIMENTAL
Intervention: levofloxacin-containing bismuth quadruple therapy (RBAL)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: standard bismuth quadruple therapy (RBMT)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: levofloxacin-containing triple therapy (RAL)
Number of subjects: 329
Study: 25727139

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) for 1 hour at 20Hz
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES)
Number of subjects: 36
Study: 23998516

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (35,000 IU/wk)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 21248398

Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid with ketorolac (3 weekly injections of HA with ketorolac followed by 2 weekly injections of HA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intra-articular hyaluronic acid alone (5 weekly injections of HA)
Number of subjects: 43
Study: 19685727

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment applied to Baihui (GV 20), Danzhong (CV 17), Zhongwan (CV 12) for 14 sessions, once every other day.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Non-acupoints (2 cm from the specified acupoints) for 14 sessions, once every other day.
Number of subjects: 70
Study: 17699988

Group type: COMPARATOR
Intervention: Bupivacaine 1.875 mg/kg alone (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bupivacaine 1.875 mg/kg with 2 microg/kg neostigmine (Group BN 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bupivacaine 1.875 mg/kg with 3 microg/kg neostigmine (Group BN 3)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bupivacaine 1.875 mg/kg with 4 microg/kg neostigmine (Group BN 4)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study: 15336476

Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis
Number of subjects: 548

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 548
Study: 11426767

Group type: EXPERIMENTAL
Intervention: DHCA alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DHCA plus retrograde brain perfusion (RBP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Antegrade perfusion (ANTE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Coronary bypass (CAB) control
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DHCA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: RBP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ANTE
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hemiarch repairs with DHCA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hemiarch repairs with ANTE
Number of subjects: 30
Study: 10731735

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 64

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 64
Study: 7973143

Group type: EXPERIMENTAL
Intervention: Intact whole milk (360 mL)
Number of subjects: 205

Group type: COMPARATOR
Intervention: 90% lactose-hydrolyzed milk (360 mL)
Number of subjects: 205
Study: 2537239

Group type: EXPERIMENTAL
Intervention: Topical tar treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: PUVA treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: UVB treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Untreated psoriatics
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normal healthy volunteers
Number of subjects: 56
Study: 793565

Group type: EXPERIMENTAL
Intervention: Duopect (narcotine hydrochloride + glyceryl guiacolate)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Narcotine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 31852380

Group type: EXPERIMENTAL
Intervention: 100 or 300 μg/kg of rVIIa-FP
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: rVIIa-FP
Number of subjects: 9

Group type: COMPARATOR
Intervention: rFVIIa (eptacog alfa)
Number of subjects: 9
Study: 30582447

Group type: EXPERIMENTAL
Intervention: Inhaled nebulized albuterol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 28126423

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT application with tension)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham (non-elastic tape application without tension)
Number of subjects: 16
Study: 25926678

Group type: EXPERIMENTAL
Intervention: Ivabradine 5 mg twice a day + standard medical therapy (bisoprolol 1.25 mg once daily)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard medical therapy (bisoprolol 2.5 to 3.75 mg once daily)
Number of subjects: 81
Study: 23356124

Group type: EXPERIMENTAL
Intervention: Polar FA20 accelerometer (PA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 28
Study: 22488183

Group type: EXPERIMENTAL
Intervention: Cold fluid (2°C)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control fluid (37°C)
Number of subjects: 7
Study: 19235853

Group type: EXPERIMENTAL
Intervention: Intradermal influenza vaccination with half the antigenic content
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional intramuscular vaccination
Number of subjects: 0
Study: 16534045

Group type: EXPERIMENTAL
Intervention: Pharmacist counseling at discharge and a follow-up telephone call 3 to 5 days later.
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (no pharmacist counseling).
Number of subjects: 178
Study: 14515043

Group type: EXPERIMENTAL
Intervention: Factor V Leiden mutation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venous thromboembolism
Number of subjects: 0
Study: 11144401

Group type: EXPERIMENTAL
Intervention: Cefdinir oral suspension
Number of subjects: 715

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate potassium, cefprozil, azithromycin (Control)
Number of subjects: 715
Study: 9058627

Group type: EXPERIMENTAL
Intervention: Rectal enemas containing butyrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rectal enemas containing a mixture of short-chain fatty acids (SCFAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo (control)
Number of subjects: 0
Study: 7940601

Group type: EXPERIMENTAL
Intervention: 1 g of vitamin-C administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (normal hepatic function)
Number of subjects: 10
Study: 3763291

Group type: EXPERIMENTAL
Intervention: MMRV vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: MMR + V vaccine
Number of subjects: 100
Study: 30580974

Group type: EXPERIMENTAL
Intervention: Daily preventive zinc tablets (7 mg/d)
Number of subjects: 3407

Group type: EXPERIMENTAL
Intervention: High‐zinc, low‐iron micronutrient powder (10 mg/d zinc, 6 mg/d iron, and 13 other micronutrients)
Number of subjects: 3407

Group type: EXPERIMENTAL
Intervention: Therapeutic zinc supplementation for diarrhea (20 mg/d for 10 days per episode)
Number of subjects: 3407

Group type: COMPARATOR
Intervention: Daily placebo powder
Number of subjects: 3407
Study: 29257995

Group type: EXPERIMENTAL
Intervention: Parenting stress, parent perceived child vulnerability, parental hostility towards the child, lower educational levels of the mother
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Age of the child
Number of subjects: 59
Study: 25787216

Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ranibizumab combined with photodynamic therapy (PDT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups (Ranibizumab monotherapy and combination therapy)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Combination therapy (PDT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Higher baseline BCVA and integrity of IS/OS junction at month 12
Number of subjects: 34

Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 34
Study: 25326876

Group type: EXPERIMENTAL
Intervention: Intensive portfolio diet
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Routine portfolio diet
Number of subjects: 351

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 351
Study: 22042366

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicin and fluorouracil (CEF)
Number of subjects: 639

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate and fluorouracil (CMF)
Number of subjects: 639
Study: 20381283

Group type: EXPERIMENTAL
Intervention: Warfarin genotyping
Number of subjects: 896

Group type: EXPERIMENTAL
Intervention: Warfarin genotyping (per-protocol analysis)
Number of subjects: 896

Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 896
Study: 18060244

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (ASA and clopidogrel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized fixed dose antiplatelet therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual determination of platelet function
Number of subjects: 0
Study: 16171866

Group type: EXPERIMENTAL
Intervention: Pyrimethamine/sulfadiazine
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 59
Study: 12766123

Group type: EXPERIMENTAL
Intervention: Actovegin plus 0.02% (wt/wt) hEGF
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Actovegin plus 0.04% (wt/wt) hEGF
Number of subjects: 61

Group type: COMPARATOR
Intervention: Actovegin 5% cream (Control)
Number of subjects: 61
Study: 10655920

Group type: EXPERIMENTAL
Intervention: Etomidate in propylene glycol formulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Etomidate in lipid emulsion formulation
Number of subjects: 20
Study: 8877243

Group type: EXPERIMENTAL
Intervention: Nasal decongestant-antihistamine (nasal oxymetazolone and oral syrup containing brompheniramine and phenylpropanolamine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (nasal saline and oral syrup)
Number of subjects: 0
Study: 1688268

Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Delagil
Number of subjects: 39
Study: 6356280

Group type: EXPERIMENTAL
Intervention: Oxacillin plus rifampin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Oxacillin alone
Number of subjects: 56
Study: 30819162

Group type: COMPARATOR
Intervention: STarT Back Tool (STarT-G) classification
Number of subjects: 294

Group type: COMPARATOR
Intervention: Prognostic model including STarT-Classification, global health, and disability at baseline
Number of subjects: 294